0
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
2/5/2025, 9:05 AM
Summary of Bill HR 679
The FDA's modifications to the risk evaluation and mitigation strategy for mifepristone have been a point of contention, with some arguing that the changes have made it more difficult for individuals to access the medication. This bill is intended to address these concerns and ensure that individuals have continued access to mifepristone for medical purposes.
In addition to nullifying the FDA's modifications, the bill also includes provisions for other purposes related to the regulation of mifepristone. The specifics of these additional provisions are not detailed in the summary, but they are likely to address various aspects of the regulation and use of the medication. Overall, Bill 119 hr 679 is focused on reversing recent changes to the risk evaluation and mitigation strategy for mifepristone and ensuring continued access to the medication for medical purposes. The bill is likely to spark debate and discussion among lawmakers and stakeholders in the healthcare and reproductive rights communities.
Congressional Summary of HR 679
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.
In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.
The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
